CTLA4 and cancer: One of the major advantages in cancer immunotherapy involves the antibody-mediated blockade of co-inhibitory “checkpoint” molecules, including cytotoxic T lymphocyte-associated protein 4 (CTLA4) and programmed death-1 (PD-1) [2, 4].